clinical parameter | num | categories |
---|---|---|
age | 6 | (1) <40 (2) 40 to 49 (3) 50 to 59 (4) 60 to 69 (5) 70 to 79 (6) > 79 |
sample type | 3 | (1) biopsie before chemotherapy (2) biopsie after chemotherapy (3) operation (after chemotherapy) |
BMI | 3 | (1) normal (18.5 to 25) (2) overweight (25 to 30) (3) obese (> 30) |
native country | 6 | (1) Germany (2) Poland (3) Russia (4) Taiwan (5) Sri Lanka (6) Turkey |
ethnic group | 2 | (1) Europe (2) Asia |
nursing | 2 | (1) no (2) yes |
nursing period | 4 | (1) none (2) short (1 to 5 months) (3) intermediate (6 to 14 months) (4) long (> 14 months) |
menopause | 2 | (1) no (2) yes |
smoking | 5 | (1) always non-smoker (2) sometimes (3) regular (4) often (5) again non-smoker |
alcohol | 5 | (1) never (2) no longer (3) less than once a month (4) 1 to 3 times a week (5) daily |
sport | 3 | (1) nothing (0 h/week) (2) little (1 to 4 h/week) (3) plenty (> 5 h/week) |
sleep | 3 | (1) little (< 7 h/day) (2) normal (7-9 h/day) (3) plenty (> 9 h/day) |
familial breast cancer | 2 | (1) No (2) yes |
histology | 4 | (1) ductal (2) lobar (3) not definable (4) mucous ductal |
T (tumor dimension) | 5 | (1) T0 (2) T1 (3) T2 (4) T3 (5) T4 |
N (lymph nodes) | 3 | (1) N0 (2) N1 (3) N2 |
Grading | 2 | (1) G2 (2) G3 |
Progesterone receptor IHC | 3 | (1) negative (0 to 1) (2) intermediate (2 to 8) (3) high positive (9 to 12) |
Estrogen receptor IHC | 3 | (1) negative (0 to 1) (2) intermediate (2 to 8) (3) high positive (9 to 12) |
Her2-new | 3 | (1) negative (2) intermediate (3) positive |
intended operation | 5 | (1) ablatio and axilla (2) ablatio and sentinel (3) BET and sentinel (4) ablation (5) BET |
inspection | 4 | (1) no conspicuity (2) in ammatory mamma-carcinoma (3) plateau phenomenon (4) other |
lateral acoustical shadow | 2 | (1) no (2) yes |
dorsal acoustic attenuation | 2 | (1) no (2) yes |
axilla | 2 | (1) unsuspicious (2) suspicious |
tumor size (mammogramm) | 3 | (1) small (0 to 9 mm) (2) intermediate (10 to 25 mm) (3) large (> 26 mm) |
micro lime | 2 | (1) no (2) yes |
chemoregime | 5 | (1) TAC (2) ACDoc (3) Geparquattro (4) FEC (5) Geparquinto |
herceptin treatment | 2 | (1) no (2) yes |